This just goes to show PAR will also likely qualify for fast-track designation.
LNA043 appears to be just beginning phase 2b studies, so is a long way off from potential approval. I doubt they will get accelerated approval for OA, but it looks like they still have a long way to go.
Novartis LNA043, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |